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Abstract: Laboratory-speciﬁc reference values for cerebrospinal
ﬂuid (CSF) Alzheimer disease (AD) biomarkers are necessary. Our
objective was to apply well-known CSF biomarkers and rede-
termine their diagnostic cutoﬀ values for AD in South Korea. CSF
samples from matched control subjects (n=71), patients with AD
dementia (ADD, n=76), and other neurological disorders with
cognitive decline (OND, n=47) were obtained from 6 Korean
dementia clinics according to a standardized protocol. CSF bio-
marker concentrations were measured using enzyme-linked
immunosorbent assay. CSF biomarkers diﬀered signiﬁcantly
between the ADD and control groups (P<0.001 for all), and
between the ADD and OND groups (P<0.001 for all). The areas
under the curve in diﬀerentiation of ADD from control subjects
were 0.97 for Ab42, 0.93 for total tau (tTau), 0.86 for pTau, and
0.99 for both tTau/Ab42 and pTau/Ab42 ratios. Our revised cutoﬀ
value for Ab42 was higher than our previous one, whereas the
values for the Tau proteins were similar. The tTau/Ab42 ratio had
the highest accuracy, 97%. Our ﬁndings highlight the usefulness of
CSF AD biomarkers in South Korea, and the necessity of con-
tinually testing the reliability of cutoﬀ values.
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A decrease in b-amyloid 1-42 (Ab42) and an increase intotal tau (tTau) and phosphorylated tau at threonine
181 (pTau181) cerebrospinal ﬂuid (CSF) levels are useful
for the early diagnosis of Alzheimer disease (AD).1–3 These
CSF proﬁles are incorporated as a supplementary tool to
the recent AD diagnostic criteria recommended by the
International Working Group-24 and the National Institute
on Aging and the Alzheimer’s Association workgroups.5
However, high between-laboratory variability presents a
serious obstacle to the sharing of biomarker data among
research and clinical centers.6,7 A global quality control
program has been initiated to minimize interlaboratory
variability8 and develop a shared protocol for preanalytical
procedures.9,10 However, the establishment of laboratory-
speciﬁc cutoﬀ values is necessary to maintain internal
consistency.7,11 Furthermore, it is necessary to continually
test the reliability of established CSF AD biomarker cutoﬀs
in large populations using updated methods to ensure their
clinical usefulness.11
Previously, we determined cutoﬀ values for the diag-
nosis of AD in a preliminary study using a small number of
CSF samples.12 In the present study, we used a larger
sample size, the updated version of the INNOTEST
enzyme-linked immunosorbent assay (ELISA) kit, and the
consensus protocol for preanalytical procedures13 to
determine new diagnostic cutoﬀ values for the diagnosis of
AD in the South Korea. Furthermore, we tested the validity
of the cutoﬀ values determined by laboratories using large
sample sizes14–18 by applying their values to our subjects.
METHODS
Subjects
CSF samples were obtained from 194 subjects [71
controls, 76 patients with AD dementia (ADD), and 47
patients with other neurological disorders with cognitive
decline (OND)] from 6 Korean dementia clinics between
April 2013 and 2016. The protocol was approved by the
local Ethical Review Board and followed the principles of
the Declaration of Helsinki. All subjects and their care-
givers (in cases of dementia) provided written informed
consent before participating in the study.
All participants with ADD (n=76) and OND (n=47)
underwent comprehensive neurological, laboratory, and
neuropsychological examinations, as well as magnetic reso-
nance imaging before CSF collection (0.5±0.2mo interval)
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following the protocol established by the Clinical Research
Center for Dementia of South Korea (CREDOS).19 Fur-
thermore,18 ﬂuorodeoxyglucose-positron emission tomog-
raphy and amyloid- positron emission tomography was per-
formed, respectively, in 37 and 11 patients with dementia.
The clinical diagnosis of AD was based on the revised clinical
criteria for probable AD established by the National Institute
on Aging and the Alzheimer’s Association workgroups.5 The
OND group included autoimmune encephalitis (n=3), cor-
ticobasal degeneration (n=1), dementia with Lewy bodies
(n=5), epilepsy (n=3), frontotemporal lobar degeneration
(n=12), metabolic encephalopathy (n=2), major depres-
sion (n=2), normal pressure hydrocephalus (n=5), Par-
kinson disease dementia (n=5), progressive supranuclear
palsy (n=1), spinocerebellar ataxia (n=1), and vascular
dementia (n=7).
The age-matched controls (n=71) were recruited
longitudinally from subjects who underwent neuroimaging
for various reasons (headache, dizziness, or health screen-
ing) or who were scheduled to undergo spinal anesthesia for
orthopedic surgery within a week. They underwent neuro-
psychological testing, neuroimaging, and CSF collection.
Control subjects were excluded if they had a history of
cognitive complaints or signiﬁcant disorders that could
potentially aﬀect cognitive function or if abnormalities were
revealed by the cognitive test or neuroimaging study
(magnetic resonance imaging in 34 and computed tomo-
graphy in 37).
All subjects were followed for at least 6 months,
beginning either before or after the lumbar puncture, to
ensure that the clinical diagnoses were accurate, and
uncertain cases were excluded from the study. The results of
the CSF AD biomarkers were not considered in the clinical
diagnosis.
APOE Genotype
Genomic DNA was extracted from all participants
using a commercially available kit (QIAGEN, Venlo, the
Netherlands). APOE genotyping was performed by poly-
merase chain reaction using an APOE genotyping PrimerMix
Kit (BioCore, Seoul, Korea) according to the manufacturer’s
recommendations.
CSF Sampling and Analysis
The CSF sampling and storage protocols have been
described previously.13 Brieﬂy, CSF was obtained via
lumbar puncture between 8:00 AM and noon. The ﬁrst 1 to
2mL of CSF was used for a routine evaluation and the next
10mL were collected into 15-mL polypropylene tubes
(#352096; BD Falcone, Bedford, MA). The CSF samples
were centrifuged at 2000g for 10 minutes at room temper-
ature within 4 hours of collection. Directly, 400 mL of
supernatant was aliquoted into 500-mL polypropylene
CryoTubes with screw caps (#72.730.006 or 72.730.005;
Sarstedt, Nu¨mbrecht, Germany) and stored at 801C until
assayed. Stored samples were packed in dry ice. CSF
analyses were performed in a biomarker core laboratory.
The samples were analyzed using the improved version of
the INNOTEST ELISA kit (Fujirebio Diagnostics, Ghent,
Belgium), which provides ready-to-use antibody calibrators
and run validation controls in place of concentrated
standards.20–22 Eight CSF samples were analyzed, including
3 pooled samples, in the initial comparison between the
runs. The 3 pooled specimens were then used to monitor
additional runs.
Statistical Analysis
The normality of the continuous variables was tested
using the Shapiro-Wilk test. CSF Ab42, tTau, and pTau181
values were log-transformed because of skewed dis-
tributions, and the logarithmic values were used for
between-group comparisons. Associations between the AD
biomarkers and diagnostic groups were assessed using
analysis of variance followed by Tukey post hoc test. w2
tests were used to compare categorical variables. Multiple
linear regression analysis was used to investigate the inﬂu-
ence of age and APOEE4 carrier status on CSF AD bio-
marker validity. Receiver operating characteristic (ROC)
curves were generated, and areas under the curve (AUCs)
with 95% conﬁdence intervals (CI) were used to identify
CSF AD biomarkers that diﬀerentiated patients with ADD
from control subjects. The cutoﬀs for individual bio-
markers were the scores that yielded the maximum Youden
index (sensitivity+ speciﬁcity1). The sensitivity and
speciﬁcity were calculated for each cutoﬀ value. All stat-
istical tests were conducted using the Statistical Package for
the Social Sciences version 19.0 (SPSS Inc., Chicago, IL).
P<0.05 were deemed to indicate statistical signiﬁcance.
Bonferroni correction was used to adjust for multiple
comparisons.
RESULTS
Demographic and clinical characteristics of the sub-
jects were compared according to the clinical diagnosis
(Table 1). The percentage of females (P=0.019) was higher
in the ADD and control groups than in the OND group.
The Mini-Mental State Examination scores of the ADD
(17.7±6.7) was lowest followed by OND (20.3±6.1)
groups and then control subjects (28.0±1.8; P<0.001).
The clinical dementia rating and sum of box scores were
signiﬁcantly higher in the ADD (1.1±0.8 and 5.8±4.8,
respectively) and OND (1.0±1.0 and 4.8±5.3, respec-
tively) groups compared with controls (0±0; P<0.001 for
all). As expected, the percentage of APOEe4 carriers was
higher in the ADD than in the control and OND group
(P=0.002).
The interrun variability between the ELISA measure-
ments was 5.8±4.7% for Ab42, 16.3±4.2% for tTau, and
11.5±8.0% for pTau181 for the coeﬃcients of variance. The
CSF Ab42 protein levels were lowest in the ADD group
(316.1±105.7pg/mL) compared with the control
(676.0±175.1pg/mL) and OND (565.8±187.9 pg/mL)
groups (F2, 191=85.6; P<0.001), whereas the ADD group
had the highest tTau (583.0±286.4pg/mL) and pTau
(73.8±28.8 pg/mL) protein levels compared with the control
(212.5±67.3 pg/mL for tTau and 41.9±12.8pg/mL for
pTau) and OND (227.9±120.0pg/mL for tTau and
37.0±15.4 pg/mL for pTau) groups (F2, 191=90.2;
P<0.001 for tTau; F2, 191=51.1; P<0.001 for pTau)
(Fig. 1). Post hoc analysis revealed that the Ab42 levels were
lower in the OND group than in the control group
(P=0.006). However, the CSF levels of tTau and pTau were
similar between the OND and control groups (P=0.974,
0.205, respectively). As CSF AD biomarkers can be aﬀected
by age and the APOEE4 allele,23–25 and the APOEE4 allele
and sex diﬀered between the groups in our study, we per-
formed multiple linear regression analysis adjusting for age,
sex, and APOEE4 status (Table 2). The analysis revealed that
the CSF biomarkers diﬀered signiﬁcantly between the ADD
and control groups (b= 0.758, 0.743, 0.549 for Ab42,
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tTau, and pTau, respectively; P<0.001 for all), and between
the ADD and OND groups (b=0.617, 0.666, 0.642 for
Ab42, tTau, and pTau, respectively; P<0.001 for all).
We generated ROC curves to identify CSF biomarkers
that diﬀerentiated patients with ADD from control sub-
jects. The AUCs were 0.97 (95% CI, 0.95-0.99) for Ab42,
0.93 (95% CI, 0.89-0.96) for tTau, and 0.86 (95% CI, 0.80-
0.93) for pTau. The AUCs for the tTau/Ab42 and pTau/
Ab42 ratios were 0.99 (95% CI, 0.98-1.0) for both, which
was more accurate than the individual protein levels. The
cutoﬀ values that yielded the best Youden index for ADD
diagnosis were 481 pg/mL for Ab42, 326 pg/mL for tTau,
57 pg/mL for pTau, 0.55 for tTau/Ab42, and 0.10 for pTau/
Ab42. The reliability of the CSF biomarkers increased
when the tTau/Ab42 and pTau/Ab42 ratios were consid-
ered (Z95% for sensitivity and speciﬁcity) instead of indi-
vidual concentrations (Table 3).
We applied the cutoﬀs from ADD versus controls to
diﬀerentiate ADD from OND. There were 7 subjects who
had tTau/Ab ratios above the cutoﬀs for ADD (>0.55) and
8 with pTau/Ab ratios >0.10 in OND. Instead, the ability
of the CSF biomarkers to diﬀerentiate between ADD and
OND patients was newly validated using a separate ROC
analysis. The AUCs were 0.88 (95% CI, 0.80-0.95) for
Ab42, 0.90 (95% CI, 0.85-0.95) for tTau, 0.89 (95% CI,
0.83-0.95) for pTau, 0.94 (95% CI, 0.89-1.0) for tTau/Ab42,
and 0.94 (95% CI, 0.88-0.99) for pTau/Ab42. The cutoﬀ
values were 478 pg/mL for Ab42, 327 pg/mL for tTau,
48 pg/mL for pTau, 0.76 for tTau/Ab42, and 0.12 for pTau/
Ab42. The sensitivity and speciﬁcity of these values were
lower than those found in the ADD versus controls com-
parison: 93% and 70% for Ab42, 83% and 85% for tTau,
86% and 85% for pTau, 93% and 92% for tTau/Ab42, and
95% and 89% for pTau/Ab42, respectively. However,
they were higher than when we applied the cutoﬀs from
ADD versus controls to the OND subjects. Of those, the
tTau/Ab42 ratio had the greatest accuracy.
We then compared our CSF AD biomarker cutoﬀs
with those used in other laboratories to investigate the
location-speciﬁcity of these values. We restricted our
investigation to studies including large sample sizes14–18,26
and those diﬀerentiating patients with AD and normal
controls (Table 3). They commonly used the INNOTEST
ELISA kit (Innogenetics, Zwijndrecht or Ghent, Belgium).
We found that the cutoﬀ values for Ab42 and Tau proteins
determined by other laboratories were accurate when
applied to our subjects. In particular, the cutoﬀ for the
tTau/Ab42 ratio >0.52 from Duits et al14 had the highest
accuracy, with 99% sensitivity and 93% speciﬁcity
DISCUSSION
We determined new cutoﬀ values for CSF AD bio-
markers that diﬀerentiate patients with ADD from control
subjects in South Korea. The individual cutoﬀ values for
Ab42, tTau, and pTau showed good speciﬁcity and sensi-
tivity; however, the tTau/Ab42 and pTau/Ab42 ratios were
more accurate, with Z95% for all statistical measures. This
ﬁnding suggests that combined Ab42 and Tau protein levels
are a more accurate indicator of AD than individual levels,
which is consistent with previous ﬁndings.7,13,14,17,25 The
reliability of our CSF biomarker cutoﬀ values was higher
than that of previous studies reporting 75% to 90% accu-
racy in distinguishing patients with AD from control sub-
jects using ELISA.14–16,18,26,27 Several factors may have
contributed to the improved accuracy in our study,
including following the consensus protocol to reduce
TABLE 1. Demographic Data According to Clinical Diagnosis
ADD CON OND
Number 76 71 47
Sex, female [n (%)] 47 (62)y 50 (70)y 21 (45)*,w
Age (y) 61.8±8.2 60.1±7.1 64.2±12.8
Education (y) 10.2±4.6 10.1±3.8 9.1±4.4
MMSE 17.7±6.7*,y 28.0±1.8w,y 20.3±6.1*,w
CDR 1.1±0.8* 0±0w,y 1.0±1.0*
CDR-SOB 5.8±4.8* 0±0w,y 4.8±5.3*
APOEe4 carrier
[n (%)]
33 (43)*,y 14 (20)w 9 (19)w
Values are shown as the means±SD. Analysis of variance followed by
Tukey post hoc test, and w2 tests were used to assess continuous and cate-
gorical variables, respectively.
ADD indicates Alzheimer disease dementia; CDR-SOB, clinical
dementia rating-sum of box; CON, control; MMSE, Mini-Mental State
Examination; OND, other neurological disorder with cognitive decline.
*P<0.05 versus CON.
wP<0.05 versus ADD.
yP<0.05 versus OND.
FIGURE 1. The CSF levels of Ab42 (left), tTau (middle), and pTau181 (right) proteins depending on the diagnostic group. The CSF Ab42
concentrations are lowest in ADD followed by OND and then control group, whereas CSF tTau and pTau181 proteins are most
abundant in ADD than both OND and control subjects (P<0.001 in all). ANOVA with post hoc analysis using log-transformed CSF
values of the individual AD biomarkers were used for group comparisons. The box plots show median and interquartile range with the
whiskers representing 95% confidence interval (*P<0.05). ADD indicates Alzheimer disease dementia; ANOVA, analysis of variance;
CON, controls; CSF, cerebrospinal fluid; OND, other neurological disorders with cognitive decline.
Alzheimer Dis Assoc Disord  Volume 31, Number 1, January–March 2017 CSF Biomarker in Alzheimer Disease
Copyright r 2016 The Author(s). Published by Wolters Kluwer Health, Inc. www.alzheimerjournal.com | 15
preanalytical inconsistencies, use of the updated version of
the ELISA, and enrolling well-deﬁned control subjects.
Worldwide eﬀorts to reduce interlaboratory variability
by standardizing the analytical protocol, improving the
ELISA kits, and using large sample sizes is expected to
improve the reliability of CSF AD biomarkers.7,28 How-
ever, individual laboratories are reluctant to adopt estab-
lished cutoﬀ values from other institutions because
laboratory-speciﬁc cutoﬀ values are necessary to maintain
internal consistency.7 This concern was highlighted recently
when the variability in CSF biomarker cutoﬀs reported by 2
well-qualiﬁed laboratories resulted in frequent changes to
the diagnosis of AD.29 We found that established cutoﬀ
values used in other laboratories demonstrated good
reliability when used in our subjects. Our cutoﬀ values for
the individual proteins Ab42, tTau, and pTau were similar
to those reported by Mattsson et al,17 and our tTau/Ab42
ratio was similar to that of Duits et al14 In fact, the tTau/
Ab42 ratio cutoﬀ value determined by Duits et al14 had the
highest reliability in our subjects (96% overall accuracy)
and exceeded the original value of 88%. Furthermore,
although the accuracy of the individual biomarker levels
was not good, the reliability of the Ab42 and Tau protein
ratios was consistently better than that of the individual
values. However, these established cutoﬀ values may not
demonstrate the same level of accuracy in subjects from
other institutions. Further studies using larger sample sizes
from multiple institutions are necessary to determine uni-
versal cutoﬀ variables. However, our ﬁndings suggest that
the Ab42 and Tau protein ratio cutoﬀ values are more
reliable than those of the individual biomarker levels for the
extrapolation of laboratory-speciﬁc cutoﬀs to other
populations.
Compared with studies conducted in western coun-
tries, few investigations of CSF Ab42, tTau, and pTau
levels have been conducted in Asian populations.26,30,31
Furthermore, previous studies were hampered by small
sizes,30,31 the use of poorly deﬁned control groups,30 and
restricting the analysis to Tau protein data.26 We used the
established tTau protein cutoﬀ of 323 pg/mL from a Japa-
nese group26 for comparisons with our cutoﬀ value. This
value, which was similar to our tTau protein cutoﬀ value,
demonstrated high accuracy in discriminating patients with
AD from control subjects.
The revised Ab42 cutoﬀ values were signiﬁcantly
higher than those we reported previously, whereas those of
tTau and pTau were comparable with the previous values.12
Given that our new cutoﬀ value for Ab42 was similar to
that of other laboratories that measured CSF Ab42 levels
using the ELISA kits, the disparity between the 2 studies
may be due to errors in the preanalytical or analytical
procedures during our prior measurements. Furthermore,
the previous study, with its small sample size, may have
included a sampling error resulting in much lower Ab42
levels in ADD and enrolled preclinical AD patients as
controls.
This study has shortcomings. First, AD subjects in
this study were younger than the typical age distribution
seen in Korean memory clinics.19 We are concerned that
the diﬀerence in age distribution could aﬀect the results
TABLE 2. Results of Multiple Linear Regression Analyses
CSF Ab42 CSF tTau CSF pTau
b P b P b P
Age (y) 0.059 0.287 0.037 0.521 0.032 0.647
APOEE4+ 0.004 0.941 0.042 0.480 0.020 0.778
Sex 0.024 0.667 0.011 0.856 0.033 0.639
Diagnosis (ADD vs. CON) 0.758 <0.001* 0.743 <0.001* 0.549 <0.001*
Age (y) 0.018 0.810 0.003 0.962 0.038 0.600
APOEE4+ 0.006 0.937 0.005 0.941 0.038 0.601
Sex 0.025 0.736 0.098 0.173 0.118 0.105
Diagnosis (ADD vs. OND) 0.617 <0.001* 0.666 <0.001* 0.642 <0.001*
b, regression coeﬃcient.
ADD indicates Alzheimer disease dementia; CON, control; CSF, cerebrospinal ﬂuid; OND, other neurological disorder with cognitive decline.
*P<0.025 was used to correct for multiple comparisons.
TABLE 3. Comparisons of Various Diagnostic Cutoff Values in
Differentiating Patients With ADD From Control Subjects
Study Cutoﬀ Value (pg/mL)
SE
(%)
SP
(%)
Current Ab42<481 94 87
tTau>326 84 96
pTau>57 72 90
tTau/Ab42>0.55 99 95
pTau/Ab42>0.10 96 96
Duits et al14 tTau/Ab42>0.52 99 93
pTau/Ab42>0.08 99 87
Schoonenboom
et al15
(152+8.25pTau)/Ab42>1 100 89
Mulder et al16 Ab42<550 100 76
tTau>375 74 100
pTau>52 80 73
(373+0.82 tTau)/Ab42>1 100 79
Mattsson et al17 Ab42r482 95 86
tTauZ320 84 93
pTauZ52 80 73
(3.694+0.0105Tau)/(Ab42/
pTau)>1
87 99
Shoji et al26 tTau>323 84 94
Hulstaert et al18 Ab42<643 100 56
tTau>252 92 70
(240+1.18 tTau)/Ab42>1 100 83
Values in bold indicate Z90% accuracy.
AD indicates Alzheimer disease; CON, controls; SE, sensitivity; SP,
speciﬁcity.
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regarding the CSF AD biomarkers. However, this does
not seem likely because age was not signiﬁcantly related to
the CSF AD biomarker levels in the multivariate analysis.
However, an additional validation study including more
elderly subjects would be valuable for answering this
question clearly. Second, the validity of AD biomarkers
for diﬀerentiating between the ADD and OND groups was
tested including an OND group with a smaller sample size
and various diseases entities. However, our data revealed
that the levels of CSF AD biomarkers in the ADD group
were distinctly diﬀerent from those of the OND group,
and the AUCs in the ROC analysis demonstrated good
reliability, 0.88 to 0.94, which again demonstrates the
utility of the AD biomarkers. For clinical practice, it is
very important to establish a cutoﬀ for AD biomarkers in
the diﬀerential diagnosis of dementia. However, this is
challenging due to the frequency of mixed pathologies and
the low sensitivity of the clinical diagnosis of non-ADD.15
This would require a study with a large sample size of
autopsy-conﬁrmed cases.
In conclusion, we determined new CSF AD biomarker
cutoﬀ values that diﬀerentiate patients with ADD from
control subjects. Our cutoﬀs were in a similar range to
those previously reported by other laboratories, partic-
ularly the combined values of Ab42 and Tau protein levels.
We revised our previous cutoﬀ values using a larger sample
size, the updated ELISA kit, which provides standardized
solutions, and standardized protocols for the preanalytical
procedures. In contrast to the Tau protein cutoﬀ values, the
new Ab42 cutoﬀs diﬀered signiﬁcantly from those obtained
in our previous pilot study, which had a relatively small
sample size and used an earlier version of the ELISA kit.12
Our ﬁndings highlight the necessity of continually testing
the reliability of CSF AD biomarker cutoﬀs to ensure their
clinical usefulness.
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